June – July 2026 Counterfeit Drug News Roundup

Counterfeit Medicine Roundup: June and July 2026

Two months, four continents, and one theme that kept repeating: the fake product looked right.

That is the thread running through almost everything that happened across June and July. A tablet with a convincing imprint. A vial with a real batch number. A pen with the correct label. A website that looks like a pharmacy. In case after case, the only thing standing between a patient and a counterfeit was a visual judgement that nobody was equipped to make.

Here is what happened, and what it says about where the threat is going.

Europe put a number on the fake-pill problem

On 9 June, the European Union Drugs Agency published its European Drug Report 2026, and buried in it was one of the more alarming trend lines of the year. Counterfeit tablets containing nitazenes, a class of synthetic opioids that can be far more potent than heroin, are spreading fast. Ten European countries seized more than 50,000 nitazene-containing tablets in 2024. In 2023 the figure was 23,000. In 2022 it was 380.

The tablets are made to resemble prescription medicines, most often oxycodone, and to a lesser extent benzodiazepines such as diazepam and alprazolam. The agency’s own framing is the important part: the authentic appearance of these products creates a false sense of security. People taking them may have no idea they are consuming a synthetic opioid at all, and the EUDA warned that the tablets may spread to groups with no opioid tolerance, including young people.

The report landed alongside Europol’s Operation SHIELD VI enforcement results and a joint EUDA, Europol and European Medicines Agency public awareness campaign, “Stay on Top – EU vs Fake Medicines,” urging consumers to buy only from authorised sources.

That is the right message. It is also an incomplete one, because “buy from authorised sources” does not help when the counterfeit is already sitting inside a legitimate supply chain, which is exactly what happened repeatedly over these two months.

Retatrutide became the defining counterfeit story of the summer

If one product dominated the news cycle across June and July, it was a drug that does not legally exist yet.

Retatrutide is an experimental weight-loss compound still in clinical trials, not approved by any regulator anywhere in the world. It has nevertheless become one of the most widely trafficked pharmaceutical products on the internet, and the harm reports piled up quickly.

In the United Kingdom, MHRA records reported by the Daily Mail showed a man died in 2025 after taking retatrutide, with reported side effects up roughly 350 percent in 2026 compared with all of 2025, including eight suspected liver, gallbladder, pancreas and bile duct complications. One patient with acute liver failure was considered for a transplant before being stabilised.

Australian health officials issued warnings in late June after multiple cases of severe illness linked to products sold as retatrutide, including acute liver failure, kidney injury and hospitalisations, sourced through social media, beauty clinics and online sellers. Australia’s Therapeutic Goods Administration launched a wider crackdown on unapproved peptides on 10 June. New Zealand’s Medsafe followed with its own consumer advisory. Malta warned the public in mid-June. In the Netherlands, hospitals reported two people falling into comas after taking counterfeit weight-loss drugs bought online that contained only insulin. Denmark reported a sharp increase in poisonings from counterfeit weight-loss products.

In the United States, CBS News found more than 120 websites and dozens of clinics and med spas openly advertising or prescribing the drug, and reported that exposures to America’s Poison Centers had climbed to an average of 95 cases a month in early 2026, a 265 percent increase over late 2025. In July, CBS reporters bought a vial labelled as retatrutide from a New York City bodega for 95 dollars, with no age verification, no questionnaire and no prescription. The Partnership for Safe Medicines found that roughly 15 pounds of retatrutide entered the US between January and April 2026.

Two data points frame why any of this matters for authentication. First, a study of self-reported side effects among Reddit users found symptom patterns that diverged sharply from Eli Lilly’s clinical trial data, a discrepancy the researchers noted may simply mean that much of what is sold as retatrutide is not retatrutide. Second, an analysis of consumer-submitted samples from a peptide testing facility found that 71 percent of grey-market samples failed to meet FDA manufacturing standards, 15 percent contained measurable bacterial endotoxins, and 2 percent did not contain the peptide on the label at all.

Blockchain analytics firm Chainalysis put the crypto-powered grey-market peptide trade at more than 100 million dollars a year, and linked some overseas suppliers to Chinese chemical manufacturers that previously sold fentanyl and amphetamine precursors. Those firms did not exit the criminal economy. They changed product lines.

Cancer drugs kept turning up

On 4 June, sources confirmed to the International Consortium of Investigative Journalists that Mexican federal authorities had seized vials labelled as Keytruda during an operation to dismantle a counterfeit ring outside Mexico City. It was the second such operation involving vials bearing Keytruda labels. The same joint action recovered 15,000 doses of clonazepam, more than 100 counterfeit vaccines and 1,000 vaccine labels.

In early July, the World Health Organization issued a warning after batches of counterfeit Darzalex, a bone marrow cancer treatment, were found in the Maldives. Myanmar’s regulator warned of counterfeit Albutein 20% Solution circulating in the country, identifiable in part by an incorrect “IP Specification” label and a missing national registration number. Kenyan authorities warned about a counterfeit batch of the breast cancer drug Phesgo, distinguishable because the fake contained a white powder rather than the ready-to-use liquid of the genuine product.

The pattern is consistent with what ICIJ’s earlier Cancer Calculus investigation described: high-priced oncology medicines create a price gap, the price gap creates demand for cheaper supply, and criminal networks fill it using authentic batch numbers and refilled vials. When the fake carries a real lot number, serialisation alone does not resolve the question.

India ran a near-continuous enforcement campaign

Indian authorities logged counterfeit medicine actions at a rate of several per week through July.

In Puducherry, a sting operation shut down a facility producing fake Pregabalin-150 tablets as part of an international network, with 300,000 counterfeit tablets and packaging materials seized and the owner arrested. Haryana’s FDA busted a racket supplying spurious Telma-AM, a widely prescribed blood pressure combination, arresting two on 20 July; a follow-up joint raid with Delhi authorities two days later recovered a further 560 fake blister packs and uncovered an unlicensed warehouse.

Uttarakhand’s Special Task Force raided a factory in Bazpur producing spurious allopathic medicines without a licence, seizing packaging machinery and excise holograms alongside the drugs. A separate raid in Dehradun on 23 July uncovered another counterfeit manufacturing unit stocked with fake versions of leading pharma brands and their packaging material. Uttar Pradesh’s FSDA exposed an interstate network in Meerut and Baghpat that was packaging food supplements as the life-saving drug Evion 400.

Late July brought more: a fake drug and anabolic steroid manufacturing setup inside a residential apartment in Delhi’s Narela, uncovered in a two-day joint operation involving Haryana FDA and Delhi Police, and a large cache of suspected counterfeits seized in Gaya, Bihar. In Gurgaon, a court denied bail to the accused ringleader of a counterfeit Mounjaro operation dismantled in April.

The recurring detail worth noting is the packaging machinery. These are not crude operations. They are production lines with the equipment to make convincing artwork, and the holograms seized in Uttarakhand make the point better than any statistic: the security feature was manufactured on site.

Nigeria escalated on every front at once

Nigeria had one of the busiest months of any single country.

On 15 July, the Nigeria Customs Service announced the interception at Apapa Port of fake NAFDAC-labelled medicines, illicit drugs and expired pharmaceutical products with a combined duty paid value of ₦53.39 billion. The consignment initially appeared legitimate; the giveaway was a NAFDAC certificate that verification showed to be fraudulent. The same day, traders at the Bridge Head Drug Market in Onitsha handed over 192 consignments of substandard, falsified and expired medicines worth ₦435 million to NAFDAC for destruction, recovered through surveillance in the market between December 2025 and June.

NAFDAC issued Public Alert 036/2026 on 21 July over suspected counterfeits mimicking AstraZeneca’s Forxiga (dapagliflozin), detected in eastern Nigeria under the near-identical names “Forzigar” and “Foziga” and imitating the AstraZeneca logo. In June, Enugu State’s health ministry warned that counterfeit Augmentin 625mg tablets were circulating, closely resembling the genuine GSK product and carrying the same batch number, AC3N.

On the legislative side, the Senate advanced the Counterfeit Medical Products, Fake Drugs and Unwholesome Processed Foods (Prohibition and Control) Bill 2026, which proposes 15-year jail terms, asset forfeiture, victim compensation and expanded NAFDAC enforcement powers, explicitly citing online drug sales, cross-border trafficking and increasingly sophisticated counterfeiting methods as the reason the existing law needs replacing.

Elsewhere in the region, Liberia’s Medicines and Health Products Regulatory Authority seized counterfeit and substandard medicines worth around L$400,000 in Bong County and launched a five-year regulatory strengthening plan on 25 June.

Enforcement and sentencing in the United States

Four Massachusetts men were sentenced to between 12 and 18 years for running a counterfeit pill operation that used five industrial pill presses and pharmaceutical-mimicking imprint tooling to produce fakes of oxycodone, Adderall and Xanax containing fentanyl, methamphetamine or bromazolam. Prosecutors linked the scheme to more than a dozen deaths.

Two New York defendants were convicted for operating industrial-scale pill pressing machines and selling the output as prescription medication to victims in all 50 states. In New Jersey, further members of a nine-person trafficking organisation were sentenced for importing fentanyl analogues from China and pressing them into counterfeit prescription pills; five of the nine have now received a combined 685 months.

A forensic laboratory in north Louisiana warned in July that nearly one in three street tablets bearing legitimate-looking drug imprints tested as counterfeit, with fentanyl the most common substance found and blue M30 tablets the most commonly faked. Their deputy director of toxicology put it plainly: the stamps look authentic, so you probably cannot tell the difference.

Three bipartisan bills targeting pill press equipment advanced to full committee in Congress: the Fight Illicit Pill Presses Act, the PRESS Act, and the Stop Pills That Kill Act. And in early July, Alibaba and its payment subsidiary agreed to pay 600 million dollars to settle Department of Justice allegations that their platform facilitated sales of illicit medications, precursor chemicals and counterfeit pill-making equipment between 2016 and 2024.

Regulators reached for verification systems

Several governments responded structurally rather than case by case.

Pakistan’s federal cabinet approved a nationwide pharmaceutical track-and-trace system aimed at eliminating counterfeit and substandard medicines. Ukraine registered its National Organization for the Verification of Medicinal Products, a step toward a national verification system using 2D coding to authenticate packaging and align with European standards.

In the UK, the MHRA, Advertising Standards Authority and General Pharmaceutical Council issued a joint warning against advertising unlicensed weight-loss medicines or prescription-only GLP-1 products to the public. The MHRA strengthened safety warnings for botulinum toxin type A products following rare botulism cases, noting that unlicensed and counterfeit versions are especially dangerous. Four members of a criminal group that sold almost two million doses of unauthorised prescription medicines online were sentenced to nearly 15 years combined following MHRA’s Operation Lamborghini.

British experts also warned of an expected surge in counterfeit weight-loss pills now that Wegovy in tablet form has entered legitimate supply chains. Pills, they noted, are far easier for criminals to copy than injectables, and fakes made from chalk and paint can be nearly undetectable by eye. The UK regulator has seized more than 6,500 fake weight-loss products in the past three years. Counterfeiters have cloned legitimate UK pharmacy websites, and discounts on fake injections have been kept modest specifically to avoid arousing suspicion. The chair of Parliament’s health and social care committee said publicly that she has very little confidence the MHRA can protect the country against counterfeit drugs at current resourcing.

Tajikistan rounded out the international picture, dismantling an operation producing fake versions of paediatric and over-the-counter medicines including Nurofen and Paracetamol, seizing tens of thousands of bottles along with packaging materials and raw ingredients.

The through-line

Read across two months and the shape is unmistakable.

The products being faked now span the full range: opioid analgesics, blood pressure combinations, antibiotics, epilepsy drugs, oncology biologics, plasma proteins, children’s fever medicine, vitamin supplements and weight-loss injectables. The channels span the full range too: bodegas, social media, cloned pharmacy websites, wholesale consignments through major ports, and licensed hospitals in at least four countries.

And the defence, almost everywhere in these stories, was a person looking at a package and deciding whether it seemed right. A customs officer looking at a certificate. A pharmacist looking at a strip. A patient looking at a pen.

That defence failed in Kota, in Mexico City, in the Maldives, in Lagos, in Northampton, in Amsterdam. It failed not because the people involved were careless, but because the fakes were manufactured on real equipment with real batch numbers and near-perfect artwork. When the counterfeiter has the packaging machine and the hologram press, the security feature stops being a security feature. It becomes a set of instructions.

This is the case for a different model. Authentication cannot depend on what a person can notice, and it cannot depend on features that can be copied along with everything else. It has to work from properties the product already has: the artwork, the print quality, the colour, the typography, the geometry, the microscopic signature of how a genuine package was actually produced. AI can read those in seconds from an ordinary photograph, with no sticker, no code, no hardware and no change to the supply chain.

That is what non-additive authentication means, and it is why TrueMed exists. Every story above is a story about a moment when someone could not tell the real from the fake fast enough. Closing that gap is the entire job.

Want to see how AI-powered, non-additive authentication protects your products and your patients? Talk to the TrueMed team.

Sources